FDA Grants Emergency Approval for Test to Detect MERS {#s1}
=====================================================

16 July 2013 (Reuters Health \[Julie Steenhuysen\])---At the request of the Centers for Disease Control and Prevention, the US Food and Drug Administration issued an emergency authorization for a diagnostic test to detect the presence of the Middle East coronavirus.

The emergency approval follows the Health and Human Services secretary\'s determination that the virus called Middle East respiratory syndrome coronavirus (MERS-CoV), which has killed at least 40 people, poses a potential public health threat.

On 5 July a spokesperson for the World Health Organization (WHO) said MERS, which can cause fever, coughing, and pneumonia, had not yet reached pandemic potential and may simply die out.

WHO experts last month said countries at risk from MERS should put in place plans for handling mass gatherings but stopped short of recommending restrictions on travel.
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***Editorial comment.*** MERS has continued to occur in the Middle East. As of 17 July the total world count for cases was 84 with 45 deaths. Hoping that the outbreak "may simply die out" is wishful thinking as we have not yet identified a vector source, there are mild and even asymptomatic cases potentially capable of spreading the disease, mutations to more virulence may occur, and the potential for spread with the Hajj coming up in October is great. That being said, the ready availability of a diagnostic test is an important step in the direction of curtailing spread by allowing for the rapid identification and isolation of cases and, if appropriate, contacts.

Updated Recommendations for Use of VariZIG---United States, 2013 {#s2}
================================================================

(MMWR 62:574, 2013)---In December 2012, the Food and Drug Administration (FDA) approved VariZIG, a varicella-zoster immune globulin preparation for use for postexposure prophylaxis of varicella for persons at high risk for severe disease who lack evidence of immunity to varicella and for whom varicella vaccine is contraindicated. Previously available under an investigational new drug expanded access protocol, VariZIG, a purified immune globulin preparation made from human plasma containing high levels of anti--varicella-zoster virus antibodies (igG), is the only varicella-zoster immune globulin preparation currently available in the United States. VariZIG is now approved for administration as soon as possible following varicella-zoster virus exposure, ideally within 96 hours (4 days) for greatest effectiveness. The Centers for Disease Control and Prevention (CDC) recommends administering VariZIG as soon as possible after exposure to the varicella-zoster virus and within 10 days.

The decision to administer VariZIG depends on 3 factors: (1) whether the patient lacks evidence of immunity to varicella, (2) whether the exposure is likely to result in infection, and (3) whether the patient is at greater risk than the general population for varicella complications.

The CDC recommends administering VariZIG as soon as possible after exposure to varicella-zoster virus and within 10 days.

Patients without evidence of immunity to varicella who are at high risk for severe varicella and complications, who have been exposed to varicella or herpes zoster, and for whom varicella vaccine is contraindicated, should receive VariZIG. Patient groups recommended by the CDC to receive VariZIG include the following: immunocompromised patients without evidence of immunity; newborn infants whose mothers have signs and symptoms of varicella around the time of delivery (ie, 5 days before to 2 days after); hospitalized premature infants born at ≥28 weeks of gestation whose mothers do not have evidence of immunity to varicella; hospitalized premature infants born at \<28 weeks of gestation or who weigh ≤1000 g at birth, regardless of their mothers' evidence of immunity to varicella; and pregnant women without evidence of immunity.

VariZIG is supplied in 125-IU vials and should be administered intramuscularly. The recommended dose is 125 IU/10 kg of body weight, up to a maximum of 625 IU (5 vials). The minimum dose is 62.5 IU (0.5 vial) for patients weighing ≤2.0 kg and 125 IU (1 vial) for patients weighing 2.1--10.0 kg.

For patients who become eligible for vaccination, varicella vaccine should be administered ≥5 months after VariZIG administration. Any patient who receives VariZIG should be observed closely for signs and symptoms of varicella for 28 days after exposure. Antiviral therapy should be instituted immediately if signs or symptoms of varicella occur. Contraindications for VariZIG administration include a history of severe systemic reactions to human immune globulins and IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

VariZIG can be ordered from the exclusive US distributor, FFF Enterprises (Temecula, California; 800-843-7477; <http://www.fffenterprises.com>).

Obama Orders Greater Effort Against HIV/AIDS in United States {#s3}
=============================================================

15 July 2013 (Reuters Health \[Yasmeen Abutaleb\])---After fresh criticism of his record on combating HIV/AIDS, President Barack Obama on Monday ordered a stepped-up effort to deal with the HIV/AIDS epidemic in the United States.

An executive order from the White House, which follows renewed criticism of Obama\'s AIDS strategy during his visit to Africa in late June and early July, called for better coordination of the national effort. Obama\'s order said that recent studies had shown that aggressive testing and early treatment can have a significant impact on preventing transmission of the human immunodeficiency virus that causes AIDS.

The order said a working group chaired by Grant Colfax, director of the Office of National AIDS Policy, and Health and Human Services Secretary Kathleen Sebelius would have 180 days to deliver recommendations to the President. The HIV Care Continuum Working Group will gather information from federal agencies on HIV testing and care, review HIV research, and recommend ways to accelerate and improve HIV treatment and care, it said.

The new order follows recommendations this year from the US Preventive Services Task Force that all 15- to 65-year-olds be screened for HIV infection, something that will be covered under Obama\'s signature heath reform, the Affordable Care Act.

Nearly 1 in 5 of the estimated 1.1 million people with HIV in the United States are undiagnosed, and a third are still not receiving medical care, even though antiretroviral drugs can forestall the long-term health risks of the disease and cut the risk of transmission by as much as 96%.

Obama announced a National AIDS Strategy in 2010, but activists have expressed disappointment at the administration\'s work on HIV/AIDS. They said they were not optimistic that the new drive would bring significant improvement.

"There are many countries in the world where the infection rate is going down---why can\'t the United States be one of them?" said Michael Weinstein, president of the AIDS Healthcare Foundation. Over the past 10 years, the rate of new HIV infections in the United States has remained at about 50 000, according to the Centers for Disease Control and Prevention.

A study published last July by a team at Atlanta\'s Emory University found that overall infection rates among African Americans, US gay, and bisexual men rival those seen in sub-Saharan African countries that are hardest hit by HIV.

The 2010 AIDS strategy aims to slow the spread of HIV by 25% over 5 years. It focuses especially on African Americans, gay and bisexual men, Latinos, and substance abusers, groups most at risk of infection.
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Outbreak of *Salmonella* Heidelberg Infections Linked to a Single Poultry Producer---13 States, 2012--2013 {#s4}
==========================================================================================================

(MMWR 62:5553, 2013)---In June 2012, the Oregon Health Authority and the Washington State Department of Health noted an increase in the number of *Salmonella enterica* serotype Heidelberg clinical isolates sharing an identical pulsed-field gel electrophoresis pattern. In 2004, this pattern had been linked to chicken from Foster Farms by the Washington State Department of Health; preliminary 2012 interviews with infected persons also indicated exposure to Foster Farms chicken.

An investigation found a total of 134 cases from 13 states, including 33 (31%) patients who were hospitalized with no deaths. Illness onset ranged from 4 June 2012 to 16 April 2013.

Of 70 patients who responded to a questionnaire, 55 (79%) reported consuming chicken in the week before illness onset, a percentage significantly higher (*P* = .01) than the 64.9% reported in a survey of healthy persons. In addition, 8 patients reported that the chicken had been prepared in the home, but either had not been consumed or consumption was not specified. In total, 36 (71%) of 51 patients reported exposure either to Foster Farms chicken (27 patients) or to another brand likely prepared by Foster Farms.

Of 14 clinical isolates from this outbreak tested for antimicrobial susceptibility, 12 were susceptible to all antimicrobials tested, and 2 were resistant to amoxicillin/clavulanic acid, ampicillin, cefoxitin, and ceftriaxone. Four intact (ie, unopened) chicken samples from 3 Washington patients' homes were tested for *Salmonella*; all yielded the outbreak strain and were traced back to 2 Foster Farms slaughter establishments.

*Salmonella* Heidelberg is frequently isolated from retail meats and predominantly from poultry products. Raw poultry in general can have *Salmonella*, and *Salmonella* is not considered a bacterial contaminant in raw poultry from a regulatory perspective.

***Editorial comment.*** *Salmonella* species are so widespread in the animal kingdom, especially among poultry, that it should surprise no one when an outbreak occurs. Contamination of poultry with *Salmonella* is extremely common, but outbreaks tend to occur when the contamination is with a virulent strain. The only safe approach is to properly refrigerate and adequately cook all animal products and to carefully wash hands and work surfaces after they have been in contact with raw meat or poultry.
